公开(公告)号：EP2350917A1

公开(公告)日：2011-08-03

申请号：EP09819761.9

申请日：2009-10-06

申请人： Somalogic, Inc.

发明人： GOLD, Larry ,  STANTON, Marty ,  BRODY, Edward N. ,  OSTROFF, Rachel M. ,  ZICHI, Dominic ,  STEWART, Alex A.E.

IPC分类号： G06G7/58 ,  G01N33/50

CPC分类号： G01N33/57449 ,  G06F19/24

摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.

公开(公告)号：EP2748356A2

公开(公告)日：2014-07-02

申请号：EP12824991.9

申请日：2012-08-22

申请人： Somalogic, Inc.

发明人： OSTROFF, Rachel M. ,  WILLIAMS, Stephen Alaric ,  RIEL-MEHAN, Michael ,  BRODY, Edward N. ,  STEWART, Alex A.E. ,  KATO, Shintaro

IPC分类号： C40B30/04 ,  C40B40/06 ,  C40B40/10 ,  G01N33/574 ,  C12Q1/68 ,  G06F19/00

CPC分类号： G01N33/57438 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/521 ,  G01N2333/70503 ,  G01N2333/78 ,  G01N2333/805 ,  G01N2333/8121 ,  G01N2333/96433 ,  G01N2333/96494 ,  G06F19/00 ,  G06F19/20

摘要： The subject disclosure concerns methods for evaluation of renal cell carcinoma (RCC). Such methods include a method of determining of a diagnosis of the individual as having or not having RCC; determination of a prognosis of a future course of RCC; determination of disease burden; or determination of recurrence of RCC in an individual who had been apparently cured of RCC. The methods each involve the detection of the value of at least one biomarker of Table 1. The biomarker value is used, in some of the methods, to determine whether the individual does or does not demonstrate evidence of disease, and in another method, to determine the degree or a score indicative of the individual's extent of disease.

公开(公告)号：EP2771451A1

公开(公告)日：2014-09-03

申请号：EP12843012.1

申请日：2012-10-24

申请人： Somalogic, Inc.

发明人： RIEL-MEHAN, Michael ,  STEWART, Alex A.E. ,  SANDERS, Glenn ,  OSTROFF, Rachel M. ,  WILLIAMS, Stephen Alaric ,  BRODY, Edward N.

IPC分类号： C12M1/34

CPC分类号： G06F19/34 ,  G06F19/00 ,  G16H10/40

摘要： The subject invention relates to methods for obtaining biological samples of improved quality. It encompasses the identification of markers or proteins in biological samples that are altered due to variations in sample collection, handling and processing. They are also useful for correcting variations in measured results for disease biomarkers. Further, they can permit the rejection of samples or groups of samples as necessary if it is determined that their collection method was not in accordance with the predetermined protocol. Other advantages useful to the skilled artisan are described herein.

公开(公告)号：EP2761289B1

公开(公告)日：2020-02-12

申请号：EP12836076.5

申请日：2012-09-28

申请人： Somalogic, Inc.

发明人： GILL, Rosalynn Dianne ,  WILLIAMS, Stephen Alaric ,  STEWART, Alex A.E. ,  MEHLER, Robert ,  FOREMAN, Trudi ,  SINGER, Britta

IPC分类号： G01N33/68

公开(公告)号：EP2761289A1

公开(公告)日：2014-08-06

申请号：EP12836076.5

申请日：2012-09-28

申请人： Somalogic, Inc.

发明人： GILL, Rosalynn Dianne ,  WILLIAMS, Stephen Alaric ,  STEWART, Alex A.E. ,  MEHLER, Robert ,  FOREMAN, Trudi ,  SINGER, Britta

IPC分类号： G01N33/48 ,  G01N33/52

摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.